A systematic review finds neuroimaging can predict ketamine treatment response, aiding personalized psychedelic therapies.
In-depth briefings on agency actions, clinical and preclinical research, and state and federal policy — with primary sources, scores, and clear limits on claims.
A systematic review finds neuroimaging can predict ketamine treatment response, aiding personalized psychedelic therapies.
The DEA's Schedule I classification of MDMB-4en-PINACA imposes stringent controls, affecting research and industry operations.
Psyence Biomedical Ltd. launches Phase IIb trial for NPX-5, a psilocybin-based treatment, targeting symptom management in cancer patients.
The DOJ's rescheduling of marijuana could reshape drug policy, affecting research and market dynamics for psychedelics.
President Trump's order to expedite FDA psychedelic drug reviews may quicken the approval process, impacting medical use and policy.
A review of alternative treatments for treatment-resistant depression identifies psilocybin as a promising option, alongside ketamine and esketamine.
A systematic review underscores psilocybin's promise in treating depression and anxiety, focusing on neuroplasticity and brain network impacts.
A pilot study in Canada shows promise for Ketamine-Assisted Therapy in Indigenous health services, highlighting cultural adaptation and mental health improvements.
Research identifies lower synaptic density in mood-related brain areas as a factor in Parkinson's-related depression, suggesting new treatment targets.
A meta-analysis shows psilocybin therapy's promise for depression, yet underscores the need for Phase 3 trials to confirm efficacy and safety.
Esketamine, combined with sufentanil, shows promise in reducing postoperative depression in elderly colorectal cancer patients, suggesting a role in enhanced recovery protocols.
Trump's order loosens federal restrictions on psychedelics, potentially boosting research and therapy development while raising regulatory concerns.